Megestrol Acetate for Cancer-Related Anorexia and Cachexia

Introduction to Megestrol Acetate

• Megestrol acetate is a synthetic progestational agent that effectively stimulates appetite in patients with cancer-related anorexia and cachexia, with approximately 1 in 4 patients experiencing increased appetite and 1 in 12 achieving measurable weight gain, though it carries risks of thromboembolic events and increased mortality 1

Mechanism and Efficacy

• Megestrol acetate is believed to stimulate appetite through downregulation of proinflammatory cytokines that contribute to cachexia, influence on the hypothalamic appetite regulation center, and potential glucocorticoid-like effects at higher doses 1, 4, 5
• A systematic review and meta-analysis showed that patients receiving megestrol acetate were 2.57 times more likely to experience appetite improvement compared to those receiving placebo 3

Clinical Considerations and Risks

• Approximately 1 in 6 patients will develop thromboembolic phenomena, and mortality risk is increased, with 1 in 23 patients at risk of death related to treatment 2, 5
• The weight gain associated with megestrol acetate is primarily adipose tissue rather than skeletal muscle, which may limit its clinical benefit 5

Alternative and Combination Approaches

• Dexamethasone may be considered as an alternative to megestrol acetate, with similar appetite-stimulating effects but different toxicity profiles 3
• Combination therapy approaches, such as megestrol acetate plus olanzapine, L-carnitine, celecoxib, and antioxidants, may yield better outcomes, including improved lean body mass, appetite, and quality of life 2, 3

Monitoring and Duration of Therapy

• Regular assessment for thromboembolic phenomena is essential due to the significantly increased risk, and weight should be monitored to assess response 5
• The optimal duration of therapy is not well-established, but benefits should be weighed against risks, particularly for longer-term use 3, 5